engleski

Molecular markers in prostate cancer bone metastases

Hormone refractory prostate cancer is androgen resistant disease and is assigned to chemohormonal/cytotoxic combination therapy. Patients with upgraded IL-6 are given a continous low dose dexamethasone therapy. IL-11. EPO and TPO are drugs of choice (with other cytotoxic agents) in patients with thromobocytopenia. The use of CgA and PAP parameters is also discussed.

metastatic prostate cancer ; CgA ; IL-6 ; IL-11 ; dexamethasone therapy

nije evidentirano